Scientists claim to have found a vaccine against one of Alzheimer’s brain memory degenerations.
Alles Europa news reports that in a research aims to find a new treatment to target these agglomerates composed following disease , which lead to neurodegeneration and cognitive decline in the brain of a human.
“Our approach hopes to cover all the basics and overcome the above hurdles in the hope of finding a therapy that can slow the accumulation of beta amyloid and tau proteins and delay the progression of the disease in many affected people.” worldwide, “said Professor Petrovsky, one of the study’s members.
A vaccine against Alzheimer’s-linked beta amyloid and tau protein formations in the brain has been successfully tested on mice by American and Australian scientists.
Alles Europa news reports that Scientists at the Institute of Molecular Medicine and the University of California have developed a vaccine against a combination of beta amyloid proteins and tau proteins generated during the development of Alzheimer’s disease and other types of dementias.
Experiments on mice have been successful and experts plan to start clinical trials in humans soon.
The formations of beta amyloid proteins and tau proteins are believed to be the primary cause of neurodegenerative changes in the brain that lead to cognitive impairment, dementia and ultimately death.
Alzheimer’s was first described and then named after the German psychiatrist and pathologist Alois Alzheimer in 1906. In developed countries, AD is one of the most expensive diseases.
This affects approximately 6% of people 65 years of age and older. In 2015, about 1.9 million people died as a result of dementia.
In 2015, there were about 29.8 million people with asthma worldwide. Most often, it begins in people over 65, although in 4–5% of cases it is Alzheimer’s disease with an early onset.
Exercise programs can be helpful in everyday life and can potentially improve results. Behavioral problems or psychosis due to dementia are often treated with antipsychotics, but this is usually not recommended, as there is little use with an increased risk of early death.
Workloads may include social, psychological, physical, and economic elements.
No treatment stops or stops its progression, although some may temporarily improve symptoms. Affected people increasingly rely on the help of others, which often places a burden on the trustee.
Mental and physical exercises, as well as avoiding obesity, can reduce the risk of developing AD; However, evidence to support these recommendations is weak. There are no drugs or supplements that have been shown to reduce risk.
The painful process is associated with plaques and neurofibrillary tangles in the brain. The likely diagnosis is based on a medical history and cognitive tests with medical images and blood tests to rule out other possible causes. Initial symptoms are often mistaken for normal aging. Examination of brain tissue is necessary for an accurate diagnosis.
The cause of Alzheimer’s is poorly understood. It is estimated that about 70% of the risk is inherited from a person’s parents, who usually have a lot of genes. Other risk factors include a history of head injuries, depression, and hypertension.
When a person’s condition worsens, they often leave the family and society. Gradually, bodily functions are lost, which ultimately leads to death. Although the rate of progression may vary, the typical life expectancy after diagnosis is three to nine years.
The most common early symptom is difficulty remembering recent events. As the disease progresses, symptoms may include speech problems, disorientation, mood swings, loss of motivation, inability to self-care, and behavioral problems.
Alles Europa news reports Alzheimer’s disease as a chronic neurodegenerative disease that usually starts slowly and gradually worsens over time, also known as the cause of 60–70% of cases of dementia.